RJA
PETX

Raymond James & Associates’s Aratana Therapeutics, Inc. PETX Stock Holding History

Raymond James & Associates’s Portfolio PETX Stock Details PETX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-10,650
Closed -$65K – 3757
2018
Q4 		$65K Buy
+10,650
New +$65K ﹤0.01% 3359
2015
Q2 		– Sell
-18,460
Closed -$296K – 2477
2015
Q1 		$296K Buy
+18,460
New +$328K ﹤0.01% 2221
2014
Q3 		– Sell
-26,496
Closed -$414K – 2265
2014
Q2 		$414K Buy
26,496
+4,696
+22% +$66.5K ﹤0.01% 1921
2014
Q1 		$405K Buy
+21,800
New +$437K ﹤0.01% 1868

Other funds holding PETX

BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EC
Engaged Capital Newport Beach, California $303M AUM 2.09% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
JG
Jefferies Group New York $12B AUM 6.2% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
GAI
General American Investors New York $1.52B AUM 37.94% 1-Year Est. Return
GPGA
Grandeur Peak Global Advisors Salt Lake City, Utah $427M AUM 39.14% 1-Year Est. Return
Impax Asset Management Group
Impax Asset Management Group London, United Kingdom $14.3B AUM 19.8% 1-Year Est. Return

Raymond James & Associates's PETX Position: Q1 2019 in Review

Raymond James & Associates sold out of Aratana Therapeutics, Inc. (PETX) in Q1 2019, closing a stake of 10,650 shares — an estimated $65K sold.

Raymond James & Associates first reported a position in PETX in Q1 2014 and held it in 4 quarters. The position peaked at $414K in Q2 2014. 104 funds tracked by Wall St. Rank hold PETX as of Q1 2019.

  • Raymond James & Associates reported no remaining Aratana Therapeutics, Inc. position as of Q1 2019 after selling out during the quarter.
  • Raymond James & Associates sold 10,650 Aratana Therapeutics, Inc. shares in Q1 2019, an estimated $65K.
  • Raymond James & Associates first reported a position in Aratana Therapeutics, Inc. in Q1 2014 and held it in 4 quarters.
  • Raymond James & Associates's Aratana Therapeutics, Inc. position peaked at $414K in Q2 2014.
  • 104 funds tracked by Wall St. Rank held Aratana Therapeutics, Inc. as of Q1 2019.

Based on Raymond James & Associates's 13F filing for Q1 2019, filed 6 May 2019.